The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in dogs

Metabolism: Clinical and Experimental

Volumn 50, Issue 10, 2001, Pages 1234-1241

  Davis H R , Jr ^a   Pula, K K ^a   Alton, K B ^a   Burrier, R E ^a   Watkins, R W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS(4 METHOXYPHENYL) 3 (3 PHENYLPROPYL) 2 AZETIDINONE; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STEROL;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034765624     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2001.26737     Document Type: Article

References (27)

1. Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461
2. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxy phenyl)-2-azetidinone (SCH 58235): A designed, potent, orally active inhibitor of cholesterol absorption
3. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH 58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461
4. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys
5. The novel cholesterol absorption inhibitor, ezetimibe, selectively inhibits the intestinal absorption of free cholesterol in the presence and absence of exocrine pancreatic function
6. Current perspectives on statins
7. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
8. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
9. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
10. New horizons in combination drug therapy for hypercholesterolemia
11. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by ezetimibe (SCH 58235): Pooled analysis of two phase II studies
12. Animal models for the evaluation of inhibitors of HMG-CoA reductase
13. Enzymatic determination of total serum cholesterol
14. A simple method for isolation and purification of total lipides from animal tissues
15. The effect of acyl CoA: Cholesterol acyltransferase inhibition on the uptake, esterification and secretion of cholesterol by the hamster small intestine
16. Binding of lysophosphatidyl choline to the rat liver fatty acid binding protein
17. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells
18. Preclinical evaluation of lovastatin
19. Comparison of plasma profiles of lovastatin, (mevinolin), simvastatin (epistatin) and pravastatin in the dog
20. Disposition of fluvastatin, an inhibitor of HMG CoA reductase, in mouse, rat, dog, and monkey
21. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
22. Metabolism and excretion of atorvastatin in rats and dogs
23. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species
24. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
25. Metabolism of SCH 58235 in the human, rat, and dog
26. Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo
27. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin